Bio-IT World Conference & Expo 2025

We are excited to be at the 24^th Annual Bio-IT World Conference & Expo. Join us at booth #724 and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.

If you are attending, don’t miss our talk on Friday, April 4^th from 12.10 to 12.40pm, in the AI for Oncology, Precision Medicine & Health track.

“SOPHiA DDM™ for Multimodal: Advancing Precision Oncology with AI-Driven Analytics”
Paul Bernard, Data Engineer, Multimodal R&D, SOPHiA GENETICS

Join this session to explore how SOPHiA DDM™ for Multimodal is shaping the future of cancer care, one breakthrough at a time:

Discover the power of the SOPHiA DDM™ Multimodal Factory and its AI-driven capabilities,
Learn how SOPHiA GENETICS is empowering BioPharma companies to advance precision oncology and improve patient outcomes,
Dive into the application of powerful algorithms within SOPHiA DDM™ to multimodal data, uncovering predictive insights through real-world case studies.

Event Dates

April 2, 2025 - April 4, 2025

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expresseda during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services